admin, Author at Integral Molecular

Published by

FDA Accepts Integral Molecular’s Membrane Proteome Array™ Qualification Plan, Advancing the Platform for Approval as a Drug Development Tool

Philadelphia – Integral Molecular, a leader in antibody discovery technologies, is proud to announce that the FDA has accepted their Membrane Proteome Array™ (MPA) […]

Published by

Webinar Presented by Integral Molecular and The Antibody Society – How Specific are Antibody Drugs? Revealing insights from a new generation of specificity assays

Thursday, February 27, 2025 8 am PT, 10 am CT, 11 am ET View the recording Limitations of conventional specificity tools have contributed to […]

Published by

Integral Molecular Recognized as an Employer of Choice by the City of Philadelphia

Philadelphia –Integral Molecular, a leading biotechnology company in Philadelphia, is honored to announce its recognition as an Employer of Choice by the City of […]

Published by

Integral Molecular Awarded $2.7 Million to Advance the Membrane Proteome Array™ Towards FDA-Qualification as a Drug Development Tool

Integral Molecular, a leader in antibody discovery and characterization, has been awarded $2.7 million by the NIH Commercialization Readiness Pilot (CRP) Program. This funding […]

Published by

Integral Molecular Secures $8 Million NIAID Contract to Combat Emerging Viruses

Philadelphia– Integral Molecular, a leader in developing advanced technologies for the discovery of vaccines and therapeutics, is excited to announce a five-year, $8 million […]

Published by

Up to One-Third of Antibody Drugs Are Nonspecific, Study Shows

Integral Molecular’s Membrane Proteome Array™ Reveals Pervasive Binding of Antibody-Based Drugs to Unintended Targets Philadelphia– Integral Molecular, a leader in antibody discovery and characterization, […]

Published by

Integral Molecular Achieves ISO 9001 Certification for its Virology Critical Reagents Supporting Vaccine Development

Philadelphia– Integral Molecular, a leader in providing essential research tools that enable vaccine development, proudly announces the achievement of ISO 9001 certification for the […]

Published by

Antibody Startup Emerges from Stealth: Cell Surface Bio Set to Transform the $10B Antibody Reagent Market

Company debuts catalog of validated, recombinant, specific antibodies against difficult protein targets, providing only the highest quality reagents for life sciences research Philadelphia – […]

Published by

Webinar Presented by Integral Molecular and Fierce Biotech – Redefining Antibody Specificity Profiling for IND

Thursday, June 6, 2024 8 am PT, 11 am ET, 17:00 CET View the recording Assessment of antibody off-target reactivity is a regulatory requirement […]

Author: admin

FDA Accepts Integral Molecular’s Membrane Proteome Array™ Qualification Plan, Advancing the Platform for Approval as a Drug Development Tool

Webinar Presented by Integral Molecular and The Antibody Society – How Specific are Antibody Drugs? Revealing insights from a new generation of specificity assays

Integral Molecular Recognized as an Employer of Choice by the City of Philadelphia

Integral Molecular Awarded $2.7 Million to Advance the Membrane Proteome Array™ Towards FDA-Qualification as a Drug Development Tool

Integral Molecular Secures $8 Million NIAID Contract to Combat Emerging Viruses

Up to One-Third of Antibody Drugs Are Nonspecific, Study Shows

Integral Molecular Achieves ISO 9001 Certification for its Virology Critical Reagents Supporting Vaccine Development

Antibody Startup Emerges from Stealth: Cell Surface Bio Set to Transform the $10B Antibody Reagent Market

Webinar Presented by Integral Molecular and Fierce Biotech – Redefining Antibody Specificity Profiling for IND

Quick Links

Solutions

Contact Us